{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:43:39Z","timestamp":1761896619481,"version":"3.37.3"},"reference-count":32,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T00:00:00Z","timestamp":1505779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Patient adherence is a key consideration in the choice of a topical regimen for the treatment of onychomycosis. The objective of this study was to investigate patient\u2010reported outcomes (treatment utilisation, adherence and satisfaction) in onychomycosis treated with once\u2010weekly amorolfine 5% nail lacquer versus once\u2010daily ciclopirox 8% nail lacquer (Study A) or once\u2010daily urea 40% ointment\/bifonazole 1% cream combination regimen (Study B). Study A: Subjects received amorolfine and ciclopirox on opposite feet for 12\u00a0weeks. Study B: Subjects received amorolfine and urea\/bifonazole on opposite feet for 6\u20107\u00a0weeks. Assessments included subject adherence as per label, treatment preference and questionnaire. Study A: More subjects adhered to amorolfine (85%) than to ciclopirox (60%) (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.025). Overall, subjects were satisfied (95% vs 100%, respectively) and the treatments were balanced in terms of preference (50% vs 45%) at week 12. Study B: More subjects adhered to amorolfine dosage (81.8%) than to the dosage of the urea\/bifonazole combination regimen (59.1%) (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.096). At the end of study, 85.7% of subjects preferred amorolfine versus 14.3% for urea\/bifonazole. Fewer subjects experienced local side effects with amorolfine (4.5%) compared to urea (27.3%) and bifonazole (15%). Amorolfine 5% nail lacquer offers a simple and convenient treatment option, which may result in improved patient adherence and consequently lead to improved efficacy and patient satisfaction.<\/jats:p>","DOI":"10.1111\/myc.12676","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T06:03:01Z","timestamp":1505800981000},"page":"800-807","source":"Crossref","is-referenced-by-count":13,"title":["Patient\u2010reported outcomes from two randomised studies comparing once\u2010weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis"],"prefix":"10.1111","volume":"60","author":[{"given":"Martin","family":"Schaller","sequence":"first","affiliation":[{"name":"Department of Dermatology Universit\u00e4ts\u2010Hautklinik  T\u00fcbingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bardur","family":"Sigurgeirsson","sequence":"additional","affiliation":[{"name":"Department of Dermatology Faculty of Medicine University of Iceland  Reykjav\u00edk Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3099-5745","authenticated-orcid":false,"given":"Marlis","family":"Sarkany","sequence":"additional","affiliation":[{"name":"Galderma International  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,9,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12072"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-78665-0_223"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2009.12.001"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12323"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01281.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.730"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycmed.2014.10.004"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70047-2"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008986826756"},{"key":"e_1_2_7_11_1","first-page":"85","article-title":"Onychomycosis and quality of life","volume":"4","author":"Szepietowski JC","year":"2009","journal-title":"Eur Dermatol"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04167.x"},{"key":"e_1_2_7_13_1","first-page":"720","article-title":"Compliance of the patients and related influential factors on the topical antifungal treatment of onychomycosis","volume":"32","author":"Zhou ZL","year":"2011","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06174.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02850197"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.1996.tb01070.x"},{"key":"e_1_2_7_17_1","first-page":"103","article-title":"What's new in the management of psoriasis?","volume":"144","author":"Kinney MA","year":"2009","journal-title":"G Ital Dermatol Venereol"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.4.408"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09253.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2012.711756"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof1010030"},{"issue":"4","key":"e_1_2_7_22_1","first-page":"11","article-title":"Amorolfine: a review of its mode of action and in vitro and in vivo antifungal activity","volume":"9","author":"Polak A","year":"1993","journal-title":"J Am Med Assoc"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1992.tb00274.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1992.tb00277.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1992.tb00278.x"},{"key":"e_1_2_7_26_1","first-page":"19","article-title":"Amorolfine nail lacquer: once\/weekly application in onychomycosis","volume":"9","author":"Zaug M","year":"1993","journal-title":"JAMA SEA"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000345105"},{"key":"e_1_2_7_28_1","unstructured":"UriSec\u00aeCream 40% Odan Laboratories.http:\/\/www.odanlab.com\/EN\/Urisec.asp?Ptype=Branded. Accessed 15 June 2017."},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198938020-00004"},{"key":"e_1_2_7_30_1","unstructured":"Canesten\u00aeFungal Nail Treatment Set.https:\/\/canesten.com.au\/en\/skin-foot-health\/fungal-nail-infection\/treatments\/canesten-fungal-nail-treatment-set\/. Accessed 15 June 2017."},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0253-5"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12037"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1997.00024.x"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fmyc.12676","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.12676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T10:02:11Z","timestamp":1696759331000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.12676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,19]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/myc.12676"],"URL":"https:\/\/doi.org\/10.1111\/myc.12676","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"type":"print","value":"0933-7407"},{"type":"electronic","value":"1439-0507"}],"subject":[],"published":{"date-parts":[[2017,9,19]]}}}